Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue 1, 2009, Pages 16-25

  Davies, Andrew ^a,d   Cifaldi, Mary A ^b   Segurado, Oscar G ^b   Weisman, Michael H ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ABBOTT LABORATORIES   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d ICON PLC   (United Kingdom)

Author keywords

Adalimumab; Cost effectiveness; Quality adjusted life years; Rheumatoid arthritis; Tumor necrosis factor antagonist

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149526661     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080257     Document Type: Article

References (52)

1. MacGregor AJ, Silman AJ. Rheumatoid arthritis and other synovial disorders - classification and epidemiology. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 4th ed. Philadelphia: Elsevier; 2008:755-62.
2. Kremers HM, Nicola P, Crowson CS, O'Fallon M, Gabriel SE. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol 2004;31:2366-73.
3. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology Oxford 2002;41:1367-74.
4. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
5. Bukhari MA, Wiles NJ, Lunt M, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003;48:46-53.
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
7. Maini R, St. Clair EW, Breedveld R, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
8. Lipsky PE, van der Heijde D, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
9. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
10. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody to the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum 2003;48:35-45.
11. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treatment with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
12. Klareskog L, van der Heidje D, Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
13. Keystone EC, Kavanaugh AF, Sharp, JT, et al. Radiographic, clinical and functional outcomes with adalimumab (a human TNF antagonist monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
14. Breedveld FC, Weisman MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
15. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
16. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998;41:1571-82.
17. Hulsmans HM, Jacobs JW, van der Heijde, et al. The curse of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
18. van der Heijde D, van Leeuwen MA, van Riel PL, et al. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22:1792-6.
19. Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
20. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology Oxford 2004;43:906-14.
21. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis; long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
22. Goekoop-Ruiterman YP, de Vries-Fouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study: a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
23. Weisman MH. Progress toward the cure of rheumatoid arthritis? The BeSt study. Arthritis Rheum 2005;52:3326-32.
24. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33.
25. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42:588-96.
26. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
27. Albers JM, Kuper HH, Van Riel PL, et al. Socio-economic consequences of RA in the first years of the disease. Rheumatology Oxford 1999;38:423-30.
28. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of five years' follow up in 732 patients from the Early RA Study (ERAS) study. Rheumatology Oxford 2000;39:603-11.
29. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS) study. Ann Rheum Dis 2002;61:335-40.
30. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharmacy 2006;12:555-69.
31. Bansback NJ, Brennan A, Ghatnekar O. Cost-effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
32. Arias E. United States life tables, 2002. National vital statistics reports; vol. 53, no 6. Hyattsville, MD: National Center for Health Statistics; 2004.
33. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
34. Smolen JS, van der Heijde D, St. Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
35. Choi HK, Michaud K, Wolfe F. Utility measures in rheumatic disorders [abstract]. Arthritis Rheum 2002;46 Suppl:S76.
36. Anderson JJ, Wells, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
37. Scott DL, Garrood T. Quality of life measures: use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000;14:663-87.
38. Sokka T, Hakkinen A, Krishnan E, et al. Similar prediction of mortality by the Health Assessment Questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004;63:494-7.
39. Social Security Administration. Actuarial resources. Office of the Chief Actuary. Cost-of-living adjustment (COLA), national average wage index. Internet. Available from: http://www.ssa.gov/OACT/COLA/AWI.html.
40. Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7). Value Health 2002;5:452-3.
41. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
42. Kobelt G, Eberhardt K, Jonsson L. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
43. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
44. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
45. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis who have failed previous disease-modifying antirheumatic drug therapy. Ann Rheum Dis 2004;63:508-16.
46. Stern R, Wolfe F. Infliximab dose and clinical status: results of two studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45.
47. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30.
48. Ollendorf D, Massarotti E, Birbara C, et al. Frequency, predictors and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93.
49. Gilbert T, Smith D, Ollendorf D. Patterns of use, dosing and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:1-9.
50. Agarwal S, Maier A, Chibnik L, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-8.
51. Furst DE, Breedveld FC, Kalden JE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006;65 Suppl III:iii2-15.
52. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17.